Stakkestad JA - Search Results

1

Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal.

Warming L, Christoffersen C, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Warming L, et al. Among authors: stakkestad ja. Maturitas. 2003 Mar 28;44(3):189-99. doi: 10.1016/s0378-5122(02)00342-0. Maturitas. 2003. PMID: 12648882 Clinical Trial.

2

Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.

Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Alexandersen P, et al. Among authors: stakkestad ja. J Clin Endocrinol Metab. 2001 Feb;86(2):755-60. doi: 10.1210/jcem.86.2.7214. J Clin Endocrinol Metab. 2001. PMID: 11158042 Clinical Trial.

3

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Chesnut CH 3rd, et al. Among authors: stakkestad ja. J Bone Miner Res. 2004 Aug;19(8):1241-9. doi: 10.1359/JBMR.040325. Epub 2004 Mar 29. J Bone Miner Res. 2004. PMID: 15231010 Free article. Clinical Trial.

4

Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.

Cooper C, Stakkestad JA, Radowicki S, Hardy P, Pilate C, Dain MP, Delmas PD. Cooper C, et al. Among authors: stakkestad ja. Osteoporos Int. 1999;9(4):358-66. doi: 10.1007/s001980050159. Osteoporos Int. 1999. PMID: 10550454 Clinical Trial.

5

Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.

Delmas PD, Pornel B, Felsenberg D, Stakkestad JA, Radowicki S, Garnero P, Hardy P, Dain MP, Petitier B; International Study Group. Delmas PD, et al. Among authors: stakkestad ja. Am J Obstet Gynecol. 2001 Jan;184(2):32-40. doi: 10.1067/mob.2001.108328. Am J Obstet Gynecol. 2001. PMID: 11174476 Clinical Trial.

6

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.

Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C. Delmas PD, et al. Among authors: stakkestad ja. Osteoporos Int. 2004 Oct;15(10):792-8. doi: 10.1007/s00198-004-1602-9. Epub 2004 Apr 8. Osteoporos Int. 2004. PMID: 15071723 Clinical Trial.

7

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.

Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD. Recker R, et al. Among authors: stakkestad ja. Bone. 2004 May;34(5):890-9. doi: 10.1016/j.bone.2004.01.008. Bone. 2004. PMID: 15121021 Clinical Trial.

8

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Ettinger B, et al. JAMA. 1999 Aug 18;282(7):637-45. doi: 10.1001/jama.282.7.637. JAMA. 1999. PMID: 10517716 Clinical Trial.

9

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.

Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM. Delmas PD, et al. Among authors: stakkestad ja. Arthritis Rheum. 2006 Jun;54(6):1838-46. doi: 10.1002/art.21918. Arthritis Rheum. 2006. PMID: 16729277 Free article. Clinical Trial.

10

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.

Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P. Miller PD, et al. Among authors: stakkestad ja. Osteoporos Int. 2012 Jun;23(6):1747-56. doi: 10.1007/s00198-011-1773-0. Epub 2011 Sep 28. Osteoporos Int. 2012. PMID: 21953471 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters